StockNews.com Initiates Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX)

Research analysts at StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note issued on Monday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

EGRX stock opened at $0.40 on Monday. Eagle Pharmaceuticals has a one year low of $0.00 and a one year high of $14.78. The stock has a market cap of $5.19 million, a price-to-earnings ratio of 0.34 and a beta of 0.51. The company has a fifty day moving average price of $2.99 and a two-hundred day moving average price of $4.04.

Institutional Investors Weigh In On Eagle Pharmaceuticals

Several hedge funds have recently bought and sold shares of EGRX. AIGH Capital Management LLC increased its stake in shares of Eagle Pharmaceuticals by 2.1% during the second quarter. AIGH Capital Management LLC now owns 1,211,509 shares of the specialty pharmaceutical company’s stock worth $6,784,000 after purchasing an additional 25,000 shares during the period. Vanguard Group Inc. increased its position in Eagle Pharmaceuticals by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 640,754 shares of the specialty pharmaceutical company’s stock worth $3,358,000 after buying an additional 2,630 shares during the period. Perceptive Advisors LLC acquired a new stake in shares of Eagle Pharmaceuticals during the second quarter worth $971,000. Cubist Systematic Strategies LLC bought a new stake in shares of Eagle Pharmaceuticals in the second quarter valued at about $145,000. Finally, XTX Topco Ltd bought a new stake in shares of Eagle Pharmaceuticals in the second quarter valued at about $113,000. 85.36% of the stock is currently owned by institutional investors and hedge funds.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.